Glucotrack, Inc. (GCTK) Stock Price & Analysis

Glucotrack, Inc. (GCTK) fell 10.24% to USD 2.98 as of September 8, 2026 at 06:29 UTC, according to Nexqual real-time market data.

GCTK last closed at USD 2.98; the session ranged USD 2.95–3.31 on volume of 74,999 shares. Market capitalization is —, with a 52-week range of USD 2.95–212.1 (NCM). Source: Nexqual, September 8, 2026 at 06:29 UTC.

Key Statistics (as of September 8, 2026 at 06:29 UTC)

Technical Analysis (GCTK)

Nexqual's technical model rates GCTK "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:29 UTC.

From Glucotrack, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe our technology, if successful, has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under development.   Further to the above progress on the Glucotrack CBGM, we have also successfully demonstrated continuous glucose sensing in the epidural space.
• Our approach is based on design elements, implant techniques, and implant tools commonly used for active implantable devices in the cardiovascular space.
• Since then, we have developed a dual supply source for both implantable system components (the electronics assembly and the sensor lead), both of which are ISO 13485 certified with dedicated experience in manufacturing active implantable medical devices.
• This will enable us to craft a reimbursement strategy that is best suited to our Glucotrack CBGM and reflects the different healthcare providers that may be involved in utilizing the product.   Our reimbursement strategy also incorporates coverage for the product, the implantation procedure, and the removal and reinsertion procedures.

Partnerships

• Both organizations have since manufactured products used in various Glucotrack pre-clinical bench and animal studies, as well products used in both our human clinical trials.   Also in 2024, we worked with The Technology Partnership, or "TTP" (Cambridge, UK) to demonstrate a sensor longevity of 3 years.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:29 UTC. This page is informational and not investment advice.